Matches in SemOpenAlex for { <https://semopenalex.org/work/W4242787534> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4242787534 endingPage "3060" @default.
- W4242787534 startingPage "3060" @default.
- W4242787534 abstract "3060 Background: HGS-ETR1 (TRM-1) is a fully-human high affinity monoclonal antibody directed and agonistic to the Tumor Necrosis Apoptosis Inducing Ligand (TRAIL) Receptor 1. TRAIL R1 is widely expressed on human tumor cells, is part of the tumor necrosis factor superfamily, and regulates the activation of caspases in the extrinsic pathway of apoptosis. TRM-1 mediates apoptosis via binding with TRAIL R1 and agonist induced activation of the extrinsic pathway of apoptosis. In preclinical studies TRM-1 induces apoptosis in sensitive human tumor cell lines in vitro at an IC50 of 3.3 nM and elicited both tumor growth inhibition and tumor regressions in a broad array of human tumor xenograft models at 10 mg/kg. Methods: Patients with advanced refractory solid tumors were treated with TRM-1 iv once every 28 days. Results: Currently 31 patients have received 56 courses of TRM-1 over 6 dose levels that ranged from 0.01 to 3.0 mg/kg. The median number of courses is 1 (1–6). One patient with pre-existing grade 2 peripheral neuropathy treated at the first dose-level had worsening of symptoms to grade 3, although no other patient has had drug-related toxicities ≥ grade 2. Pharmacokinetic parameters (Mean [±SD] ) at the 1 mg/kg dose level are characterized by a long elimination t1/2 of 14.4 [4.9] days, Vd that approximates plasma volume, Cl of 3.8 [1.4] mL/day/kg, Cmax of 23.6 [5.1] μg/mL, and an AUC of 290.4 [97.2] μg × days/mL. No evidence of human anti-human antibody formation has been detected. Accrual continues next at the10 mg/kg dose level. Conclusions: TRM-1 represents the first specific TRAIL R1 targeting agent and can be safely administered IV every 4 weeks at doses that reach plasma concentrations associated with activity in preclinical studies. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Human Genome Sciences Human Genome Sciences Human Genome Sciences Human Genome Sciences Human Genome Sciences" @default.
- W4242787534 created "2022-05-12" @default.
- W4242787534 creator A5006884434 @default.
- W4242787534 creator A5011905014 @default.
- W4242787534 creator A5015109908 @default.
- W4242787534 creator A5023033500 @default.
- W4242787534 creator A5040603366 @default.
- W4242787534 creator A5045107557 @default.
- W4242787534 creator A5053128814 @default.
- W4242787534 creator A5070570779 @default.
- W4242787534 creator A5076450044 @default.
- W4242787534 creator A5081246052 @default.
- W4242787534 date "2004-07-15" @default.
- W4242787534 modified "2023-10-07" @default.
- W4242787534 title "A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors" @default.
- W4242787534 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.3060" @default.
- W4242787534 hasPublicationYear "2004" @default.
- W4242787534 type Work @default.
- W4242787534 citedByCount "11" @default.
- W4242787534 crossrefType "journal-article" @default.
- W4242787534 hasAuthorship W4242787534A5006884434 @default.
- W4242787534 hasAuthorship W4242787534A5011905014 @default.
- W4242787534 hasAuthorship W4242787534A5015109908 @default.
- W4242787534 hasAuthorship W4242787534A5023033500 @default.
- W4242787534 hasAuthorship W4242787534A5040603366 @default.
- W4242787534 hasAuthorship W4242787534A5045107557 @default.
- W4242787534 hasAuthorship W4242787534A5053128814 @default.
- W4242787534 hasAuthorship W4242787534A5070570779 @default.
- W4242787534 hasAuthorship W4242787534A5076450044 @default.
- W4242787534 hasAuthorship W4242787534A5081246052 @default.
- W4242787534 hasConcept C112705442 @default.
- W4242787534 hasConcept C121608353 @default.
- W4242787534 hasConcept C126322002 @default.
- W4242787534 hasConcept C150903083 @default.
- W4242787534 hasConcept C159654299 @default.
- W4242787534 hasConcept C170493617 @default.
- W4242787534 hasConcept C17991360 @default.
- W4242787534 hasConcept C185592680 @default.
- W4242787534 hasConcept C190283241 @default.
- W4242787534 hasConcept C203014093 @default.
- W4242787534 hasConcept C207001950 @default.
- W4242787534 hasConcept C22979827 @default.
- W4242787534 hasConcept C2778938600 @default.
- W4242787534 hasConcept C502942594 @default.
- W4242787534 hasConcept C542903549 @default.
- W4242787534 hasConcept C55493867 @default.
- W4242787534 hasConcept C71924100 @default.
- W4242787534 hasConcept C86803240 @default.
- W4242787534 hasConcept C98274493 @default.
- W4242787534 hasConceptScore W4242787534C112705442 @default.
- W4242787534 hasConceptScore W4242787534C121608353 @default.
- W4242787534 hasConceptScore W4242787534C126322002 @default.
- W4242787534 hasConceptScore W4242787534C150903083 @default.
- W4242787534 hasConceptScore W4242787534C159654299 @default.
- W4242787534 hasConceptScore W4242787534C170493617 @default.
- W4242787534 hasConceptScore W4242787534C17991360 @default.
- W4242787534 hasConceptScore W4242787534C185592680 @default.
- W4242787534 hasConceptScore W4242787534C190283241 @default.
- W4242787534 hasConceptScore W4242787534C203014093 @default.
- W4242787534 hasConceptScore W4242787534C207001950 @default.
- W4242787534 hasConceptScore W4242787534C22979827 @default.
- W4242787534 hasConceptScore W4242787534C2778938600 @default.
- W4242787534 hasConceptScore W4242787534C502942594 @default.
- W4242787534 hasConceptScore W4242787534C542903549 @default.
- W4242787534 hasConceptScore W4242787534C55493867 @default.
- W4242787534 hasConceptScore W4242787534C71924100 @default.
- W4242787534 hasConceptScore W4242787534C86803240 @default.
- W4242787534 hasConceptScore W4242787534C98274493 @default.
- W4242787534 hasIssue "14_suppl" @default.
- W4242787534 hasLocation W42427875341 @default.
- W4242787534 hasOpenAccess W4242787534 @default.
- W4242787534 hasPrimaryLocation W42427875341 @default.
- W4242787534 hasRelatedWork W2004556784 @default.
- W4242787534 hasRelatedWork W2028112905 @default.
- W4242787534 hasRelatedWork W2057097799 @default.
- W4242787534 hasRelatedWork W2256490948 @default.
- W4242787534 hasRelatedWork W2370929226 @default.
- W4242787534 hasRelatedWork W2379280247 @default.
- W4242787534 hasRelatedWork W2766550598 @default.
- W4242787534 hasRelatedWork W2942467058 @default.
- W4242787534 hasRelatedWork W3000071749 @default.
- W4242787534 hasRelatedWork W3122926187 @default.
- W4242787534 hasVolume "22" @default.
- W4242787534 isParatext "false" @default.
- W4242787534 isRetracted "false" @default.
- W4242787534 workType "article" @default.